Hutchmed announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
- Hutchmed announces ESLIM-01 trial met primary endpoint
- HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
- Hutchmed initiated with a Buy at Citi
- Hutchmed sees 2023 oncology/immunology revenues $450M-$550M